Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
about
Anti-cancer potential of a novel SERM ormeloxifene.Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer.Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.Expression of mitochondrial regulators PGC1α and TFAM as putative markers of subtype and chemoresistance in epithelial ovarian carcinomaMolecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenograftsRelationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model systemThe promise and challenge of ovarian cancer models.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase.Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft modelsDefining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.Tumorgrafts as in vivo surrogates for women with ovarian cancer.A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.Therapeutic potentials of short interfering RNAs.miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation.In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen.Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
P2860
Q33649054-05EB55B3-2486-4853-8B74-80191471FFE7Q33750182-2497897B-3065-4FBC-81C2-C23B95485057Q34022694-7A89658C-CE79-4436-B3C2-2FED4F7921CAQ34223682-265C80C5-1DFB-4C29-8206-E971105E10B6Q35448716-5409058F-7A1D-446F-8B07-96B1694835E0Q35693161-B1415A01-7CD7-44E4-98A6-BB08794D598BQ35771750-1FA7915C-284C-4151-9713-216840A397D9Q35837949-0699F1FB-3FB6-4CBF-93F6-3A6E6DDCF86AQ35864802-3ACBCF45-8EBC-4ED4-9CCA-BD3994061FC9Q35953034-77E436D1-8A4D-4B0B-9DDD-2C3EDB80F0A3Q35999582-B674ABAE-E805-40C9-999E-FC703A260392Q36782553-7E2EE32E-AD70-4A0A-B3FF-B1B654756197Q37626455-D4CD55A0-1385-477D-A8CD-163CCAA51EB4Q37689036-1E3C9AF0-A1C0-4AB4-B6E8-8AC165286050Q38645080-696C42D7-1CC6-4263-A19B-7221B8BB7C0AQ38873436-A140D2D3-5506-4DF2-B7B5-294663534A8AQ39042958-515333E8-E31D-4E73-8B7F-F05BE6969854Q39183138-591809F4-96BF-47C5-A83F-93E21679A19BQ41915916-240AD257-CC98-4918-84E4-32FA524A2A2BQ42109090-B6DF9180-B6BB-41AD-8370-C36B2772BC67Q48125728-2CA241F7-384C-4DAB-8733-DA08B9637279Q50975813-CF7F0833-96E0-426A-B391-A57A9ED1B192
P2860
Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Trastuzumab and pertuzumab pro ...... ling new treatment strategies.
@en
Trastuzumab and pertuzumab pro ...... ling new treatment strategies.
@nl
type
label
Trastuzumab and pertuzumab pro ...... ling new treatment strategies.
@en
Trastuzumab and pertuzumab pro ...... ling new treatment strategies.
@nl
prefLabel
Trastuzumab and pertuzumab pro ...... ling new treatment strategies.
@en
Trastuzumab and pertuzumab pro ...... ling new treatment strategies.
@nl
P2093
P50
P1476
Trastuzumab and pertuzumab pro ...... aling new treatment strategies
@en
P2093
Charlene Kay
Dana Faratian
Max Hasmann
Michael Dodds
Morwenna Muir
Peter Mullen
Simon P Langdon
Yoko Nagumo
P304
P356
10.1158/1078-0432.CCR-10-2461
P407
P577
2011-05-13T00:00:00Z